Fundamental Analysis of TRANSCODE THERAPEUTICS INC(NASDAQ:RNAZ) stock

Fundamental Rating

Overall RNAZ gets a fundamental rating of 2 out of 10. We evaluated RNAZ against 588 industry peers in the Biotechnology industry. The financial health of RNAZ is average, but there are quite some concerns on its profitability. RNAZ does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year RNAZ has reported negative net income.

RNAZ had a negative operating cash flow in the past year.

In the past 5 years RNAZ always reported negative net income.

RNAZ had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -358.77%, RNAZ is not doing good in the industry: 94.88% of the companies in the same industry are doing better.

Looking at the Return On Equity, with a value of -1130.39%, RNAZ is doing worse than 83.28% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-358.77%
ROE	-1130.39%
ROIC	N/A

ROA(3y)-206.64%

ROA(5y)-229.13%

ROE(3y)-568.6%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RNAZ so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for RNAZ has been reduced compared to 1 year ago.

Compared to 5 years ago, RNAZ has more shares outstanding

There is no outstanding debt for RNAZ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

RNAZ has an Altman-Z score of -24.04. This is a bad value and indicates that RNAZ is not financially healthy and even has some risk of bankruptcy.

RNAZ has a worse Altman-Z score (-24.04) than 88.40% of its industry peers.

RNAZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-24.04

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 1.28 indicates that RNAZ should not have too much problems paying its short term obligations.

RNAZ has a Current ratio of 1.28. This is amonst the worse of the industry: RNAZ underperforms 86.01% of its industry peers.

A Quick Ratio of 1.28 indicates that RNAZ should not have too much problems paying its short term obligations.

RNAZ has a Quick ratio of 1.28. This is amonst the worse of the industry: RNAZ underperforms 84.64% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.28
Quick Ratio	1.28

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 31.24% over the past year.

EPS 1Y (TTM)31.24%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q92.86%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

Based on estimates for the next years, RNAZ will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.86% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y99.04%

EPS Next 2Y41.31%

EPS Next 3Y25.95%

EPS Next 5Y14.86%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

RNAZ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year RNAZ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

RNAZ's earnings are expected to grow with 25.95% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y41.31%

EPS Next 3Y25.95%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for RNAZ!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

TRANSCODE THERAPEUTICS INC

NASDAQ:RNAZ (5/3/2024, 7:16:04 PM)

After market: 0.7813 -0.04 (-4.72%)

0.82

+0.11 (+15.98%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap4.76M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-358.77%
ROE	-1130.39%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.28
Quick Ratio	1.28
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)31.24%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y99.04%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

TRANSCODE THERAPEUTICS INC (RNAZ)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens